Sundaram G S, London R, Manimekalai S, Nair P P, Goldstein P
Lipids. 1981 Apr;16(4):223-7. doi: 10.1007/BF02535020.
Twenty-six patients with clinically confirmed mammary dysplasia and five age-matched controls were treated with alpha-tocopherol, 600 mg/day. Serum samples collected on the 21st day of the menstrual cycle were analyzed for cholesterol in lipoprotein fractions, isolated by a combination of precipitation and ultracentrifugation techniques. Eighty-five percent of patients showed objective and subjective remission from disease following therapy. In mammary dysplasia patients, the ratio of serum cholesterol/high density lipoprotein cholesterol was higher than those in age-matched controls, an abnormality which was corrected by alpha-tocopherol therapy. Furthermore, as a result of therapy, high density lipoproteins increased and ester cholesterol associated with low density lipoproteins decreased. The results suggest that alpha-tocopherol may serve as an effective agent in treating patients with benign disease, as well as correct the inherent abnormality in serum cholesterol distribution in mammary dysplasia patients.
26例临床确诊为乳腺发育异常的患者和5名年龄匹配的对照者接受了α-生育酚治疗，剂量为每日600毫克。在月经周期的第21天采集血清样本，通过沉淀和超速离心技术相结合的方法分离脂蛋白组分，并分析其中的胆固醇含量。85%的患者在治疗后出现了疾病的客观和主观缓解。在乳腺发育异常患者中，血清胆固醇/高密度脂蛋白胆固醇的比值高于年龄匹配的对照者，这种异常通过α-生育酚治疗得到了纠正。此外，治疗结果显示，高密度脂蛋白增加，与低密度脂蛋白相关的酯化胆固醇减少。结果表明，α-生育酚可能是治疗良性疾病患者的有效药物，同时也能纠正乳腺发育异常患者血清胆固醇分布的固有异常。
